Nanjing Zaoming Pharmaceutical

Nanjing Zaoming Pharmaceutical is a China-based biotechnology company specializing in the discovery and development of innovative small molecule drugs, with a core focus on Targeted Protein Degradation (TPD) technologies. The company leverages its proprietary platform to design Proteolysis-Targeting Chimeras (PROTACs) and molecular glues aimed at addressing high-unmet-need indications in oncology and immunology. Their pipeline primarily targets well-validated but difficult-to-treat proteins such as the androgen receptor and Bruton tyrosine kinase. By utilizing advanced medicinal chemistry and degradation screening, Nanjing Zaoming aims to overcome resistance mechanisms associated with traditional inhibitors. The company is currently advancing several programs through the pre-clinical and IND-enabling stages.